Role of (I → 3)-β-D-glucan in the diagnosis of invasive aspergillosis

Medical Mycology

Volumn 47, Issue SUPPL. 1, 2009, Pages

  Marty, Francisco M ^a   Koo, Sophia ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Diagnosis; Galactomannan; Invasive aspergillosis; Lucan; Transplantation

Indexed keywords

ALBUMIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BETA 1,3 GLUCAN; CASPOFUNGIN; CEFAZOLIN; CEFEPIME; CEFOTAXIME; COLISTIN; COTRIMOXAZOLE; ERTAPENEM; GALACTOMANNAN; IMMUNOGLOBULIN; ITRACONAZOLE; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; BETA GLUCAN; BETA-1,3-D-GLUCAN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; ASPERGILLOSIS; CANDIDIASIS; CRYPTOCOCCUS NEOFORMANS; ENZYME ACTIVITY; FALSE POSITIVE RESULT; FUNGAL METABOLISM; FUNGEMIA; GRAM POSITIVE BACTERIUM; HEMODIALYSIS PATIENT; HUMAN; INTERMETHOD COMPARISON; INVASIVE ASPERGILLOSIS; LATEX AGGLUTINATION TEST; MYCOSIS; MYELODYSPLASTIC SYNDROME; NONHUMAN; PNEUMOCYSTIS JIROVECI; POPULATION RISK; SENSITIVITY AND SPECIFICITY; SPECIES INVASION; SYNCHRONOUS INVASIVE CANDIDIASIS; VALIDATION STUDY; ZYGOMYCETES; BLOOD; DIAGNOSTIC PROCEDURE; LABORATORY DIAGNOSIS; REVIEW;

FILOBASIDIELLA NEOFORMANS; FUNGI; PNEUMOCYSTIS JIROVECII; ZYGOMYCETES;

ASPERGILLOSIS; BETA-GLUCANS; FALSE POSITIVE REACTIONS; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; SENSITIVITY AND SPECIFICITY;

EID: 67651112218     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1080/13693780802308454     Document Type: Article

References (72)

1. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 2000; 79: 250-260.
2. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32 358-366.
3. Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: Outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007; 44: 531-540.
4. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415.
5. Caillot D, Casasnovas O, Bernard A, et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997; 15: 139-147.
6. Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001; 19: 253-259.
7. Kuhlman JE, Fishman EK, Siegelman SS. Invasive pulmonary aspergillosis in acute leukemia: Characteristic findings on CT, the CT halo sign, and the role of CT in early diagnosis. Radiology 1985; 157: 611-614.
8. Maertens J, Verhaegen J, Demuynck H, et al. Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive Aspergillosis. J Clin Microbiol 1999; 37: 3223-3228.
9. Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: A prospective validation. Blood 2001; 97: 1604-1610.
10. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: A meta-analysis. Clin Infect Dis 2006; 42: 1417-1427.
11. Obayashi T, Yoshida M, Mori T, et al. Plasma (1→3 -beta-Dglucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 1995; 345: 17-20.
12. Odabasi Z, Mattiuzzi G, Estey E, et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: Validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004; 39: 199-205.
13. Finkelman MA, Tamura H. Detection and measurement of (1→3)-beta-D-glucan with Limulus amebocyte lysate-based reagents. In: Young S-H, Castranova V (eds). Toxicology of 1-3-beta-Glucans: Glucans as a Marker for Fungal Exposure. Boca Raton: CRC Press/Taylor & Francis, 2005: 179-197.
14. Williams DL, Lowman DW, Ensley HE. Introduction to the chemistry and immunobiology of beta-glucans. In: Young S-H, Castranova V (eds). Toxicology of 1-3-beta-Glucans: Glucans as a Marker for Fungal Exposure Boca Raton: CRC Press/Taylor & Francis, 2005: 1-34.
15. Lamaris GA, Lewis RE, Chamilos G, et al. Caspofunginmediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae. J Infect Dis 2008; 198: 186-192.
16. Lehmann PF, Reiss E. Invasive aspergillosis: Antiserum for circulating antigen produced after immunization with serum from infected rabbits. Infect Immun 1978; 20: 570-572.
17. Reiss E, Lehmann PF. Galactomannan antigenemia in invasive aspergillosis. Infect Immun 1979; 25: 357-365.
18. Levin J, Bang FB. Clottable protein in Limulus; its localization and kinetics of its coagulation by endotoxin. Thromb Diath Haemorrh 1968; 19: 186-197.
19. Kakinuma A, Asano T, Torii H, Sugino Y. Gelation of Limulus amoebocyte lysate by an antitumor (1 leads to 3)-beta-D-glucan. Biochem Biophys Res Commun 1981; 101: 434-439.
20. Morita T, Tanaka S, Nakamura T, Iwanaga S. A new (1→3)-b-Dglucan- mediated coagulation pathway found in Limulus amebocytes. FEBS Lett 1981; 129: 318-321.
21. Obayashi T, Tamura H, Tanaka S, et al. A new chromogenic endotoxin-specific assay using recombined Limulus coagulation enzymes and its clinical applications. Clin Chim Acta 1985; 149: 55-65.
22. Obayashi T, Tamura H, Tanaka S, et al. Endotoxin-inactivating activity in normal and pathological human blood samples. Infect Immun 1986; 53: 294-297.
23. Obayashi T, Yoshida M, Tamura H. Determination of plasma (1→3)-beta-D-glucan: A new diagnostic aid to deep mycosis. J Med Vet Mycol 1992; 30: 275-280.
24. Federal Drug Agency. Evaluation and Safety Center for Devices and Radiological Health. Glucatell (1-3-Beta-D-Glucan Serological Assay). Updated 21 May 2004. Accessed 16 March 2006 from: http://www.fda.gov/ cdrh/pdf3/K032373.pdf
25. Odabasi Z, Paetznick VL, Rodriguez JR, et al. Differences in beta-glucan levels in culture supernatants of a variety of fungi. Med Mycol 2006; 44: 267-272.
26. Miyazaki T, Kohno S, Mitsutake K, et al. (1→3)-beta-D-glucan in culture fluid of fungi activates factor G, a Limulus coagulation factor. J Clin Lab Anal 1995; 9: 334-339.
27. Mori T, Ikemoto H, Matsumura M, et al. Evaluation of plasma (1→3)-beta-D-glucan measurement by the kinetic turbidimetric Limulus test, for the clinical diagnosis of mycotic infections. Eur J Clin Chem Clin Biochem 1997; 35: 553-560.
28. Miyazaki T, Kohno S, Mitsutake K, et al. Plasma (1→3)-beta-Dglucan and fungal antigenemia in patients with candidemia, aspergillosis, and cryptococcosis. J Clin Microbiol 1995; 33 3115-3118.
29. Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1→3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005; 41: 654-659.
30. Pazos C, Ponton J, Del Palacio A. Contribution of (1→3)-beta-Dglucan chromogenic assay to diagnosis and therapeutic monitoring monitoring of invasive aspergillosis in neutropenic adult patients: A comparison with serial screening for circulating galactomannan. J Clin Microbiol 2005; 43: 299-305.
31. Pickering JW, Sant HW, Bowles CA, Roberts WL, Woods GL. Evaluation of a (1→3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 2005; 43: 5957-5962.
32. Yoshida M, Obayashi T, Iwama A, et al. Detection of plasma (1→3)-beta-D-glucan in patients with Fusarium, Trichosporon, Saccharomyces and Acremonium fungaemias. J Med Vet Mycol 1997; 35: 371-374.
33. Reiss E, Obayashi T, Orle K, Yoshida M, Zancope-Oliveira RM. Non-culture based diagnostic tests for mycotic infections. Med Mycol 2000; 38: 147-159.
34. Iwama A, Yoshida M, Miwa A, et al. Improved survival from fungaemia in patients with haematological malignancies: Analysis of risk factors for death and usefulness of early antifungal therapy. Eur J Haematol 1993; 51: 156-160.
35. Koo S, Bryar J, Page JH, Baden LR, Marty FM. Clinical utility of (1→3)-β-D-Glucan Assay (BG) in the diagnosis of invasive fungal infections (Abstract M-1600). 46th Annual Interscience Conference on Antimicrobial Agents & Chemotherapy; 2006; San Francisco, CA.
36. Mitsutake K, Miyazaki T, Miyazaki H, et al. [Evaluation of (1-3)- beta-D-glucan in aspergillosis and cryptococcosis]. Nihon Kyobu Shikkan Gakkai Zasshi 1994; 32: 37-41.
37. Yasuoka A, Tachikawa N, Shimada K, Kimura S, Oka S. (1→3) beta-D-glucan as a quantitative serological marker for Pneumocystis carinii pneumonia. Clin Diagn Lab Immunol 1996; 3: 197-199.
38. Marty FM, Koo S, Bryar J, Baden LR. (1→3)beta-D-glucan assay positivity in patients with Pneumocystis (carinii) jiroveci pneumonia. Ann Intern Med 2007; 147: 70-72.
39. Tasaka S, Hasegawa N, Kobayashi S, et al. Serum indicators for the diagnosis of pneumocystis pneumonia. Chest 2007; 131: 1173-1180.
40. Yoshioka T, Ikegami K, Ikemura K, et al. A study on Limulus amebocyte lysate (LAL) reactive material derived from dialyzers. Jpn J Surg 1989; 19: 38-41.
41. Kanda H, Kubo K, Hamasaki K, et al. Influence of various hemodialysis membranes on the plasma (1→3)-beta-D-glucan level. Kidney Int 2001; 60: 319-323.
42. Kato A, Takita T, Furuhashi M. Elevation of blood (1→3 -beta-D-glucan concentrations in hemodialysis patients. Nephron 2001; 89: 15-19.
43. Ikemura K, Ikegami K, Shimazu T, Yoshioka T, Sugimoto T. False-positive result in Limulus test caused by Limulus amebocyte lysate-reactive material in immunoglobulin products. J Clin Microbiol 1989; 27 1965-1968.
44. Ogawa M, Hori H, Niiguchi S, Azuma E, Komada Y. Falsepositive plasma (1→3)-beta-D-glucan test following immunoglobulin product replacement in an adult bone marrow recipient. Int J Hematol 2004; 80: 97-98.
45. Usami M, Ohata A, Horiuchi T, et al. Positive (1→3 -beta-Dglucan in blood components and release of (1→3)-beta-D-glucan from depth-type membrane filters for blood processing. Transfusion 2002; 42 1189-1195.
46. Nagasawa K, Yano T, Kitabayashi G, et al. Experimental proof of contamination of blood components by (1→3)-beta-D-glucan caused by filtration with cellulose filters in the manufacturing process. J Artif Organs 2003; 6: 49-54.
47. Ohata A, Usami M, Horiuchi T, Nagasawa K, Kinoshita K. Release of (1→3)-beta-D-glucan from depth-type membrane filters and their in vitro effects on proinflammatory cytokine production. Artif Organs 2003; 27: 728-735.
48. Kimura Y, Nakao A, Tamura H, Tanaka S, Takagi H. Clinical and experimental studies of the Limulus test after digestive surgery. Surg Today 1995; 25: 790-794.
49. Nakao A, Yasui M, Kawagoe T, et al. False-positive endotoxemia derives from gauze glucan after hepatectomy for hepatocellular carcinoma with cirrhosis. Hepatogastroenterology 1997; 44: 1413-1418.
50. Mohr J, Paetznick VL, Rodriguez JR, et al. A prospective pilot survey of B-glucan (BG) seropositivity and its relationship to invasive candidiasis (IC) in the surgical ICU (SICU) (Abstract M-168). 45th Annual Interscience Conference on Antimicrobial Agents & Chemotherapy; 2005; Washington, DC.
51. Sulahian A, Touratier S, Ribaud P. False positive test for Aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam. N Engl J Med 2003; 349: 2366-2367.
52. Viscoli C, Machetti M, Cappellano P, et al. False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin-tazobactam. Clin Infect Dis 2004; 38: 913-916.
53. Marty FM, Lowry CM, Lempitski SJ, et al. Reactivity of (1→3)- beta-d-glucan assay with commonly used intravenous antimicrobials. Antimicrob Agents Chemother 2006; 50: 3450-3453.
54. Mennink-Kersten MA, Warris A, Verweij PE. 1,3-beta-D-glucan in patients receiving intravenous amoxicillin-clavulanic acid. N Engl J Med 2006; 354: 2834-2835.
55. Digby J, Kalbfleisch J, Glenn A. Serum glucan levels are not specific for presence of fungal infections in intensive care unit patients. Clin Diagn Lab Immunol 2003; 10: 882-885.
56. Senn L, Robinson JO, Schmidt S, et al. 1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis 2008; 46: 878-885.
57. Tanaka S, Aketagawa J, Takahashi S. Inhibition of high-molecular- weight-(1→3)-beta-D-glucan-dependent activation of a Limulus coagulation factor G by laminaran oligosaccharides and curdlan degradation products. Carbohydr Res 1993; 244: 115-127.
58. Zhang GH, Baek L, Buchardt O, Koch C. Differential blocking of coagulation-activating pathways of Limulus amebocyte lysate. J Clin Microbiol 1994; 32: 1537-1541.
59. Aisenberg G, Rolston KV, Safdar A. Bacteremia caused by Achromobacter and Alcaligenes species in 46 patients with cancer (1989-2003). Cancer 2004; 101: 2134-2140.
60. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 2002; 34: 7-14.
61. Senn L, Robinson JO, Schmidt S, et al. 1,3-beta-d-Glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis 2008; 46: 878-885.
62. Kami M, Tanaka Y, Kanda Y, et al. Computed tomographic scan of the chest, latex agglutination test and plasma (1AE3)-beta-Dglucan assay in early diagnosis of invasive pulmonary aspergillosis: A prospective study of 215 patients. Haematologica 2000; 85: 745-752.
63. Kawazu M, Kanda Y, Nannya Y, et al. Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1→3)-beta-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders. J Clin Microbiol 2004; 42: 2733-2741.
64. Haynes RB. Clinical Epidemiology: How to do Clinical Practice Research, 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2006.
65. Upton A, LeisenringW, Marr KA. (1→3) beta-D-glucan assay in the diagnosis of invasive fungal infections. Clin Infect Dis 2006; 42: 1054-1056; author reply 6.
66. Hashimoto A, Yamakami Y, Kamberi P, et al. Comparison of PCR, (1→3)-beta-D-glucan and galactomannan assays in sera of rats with experimental invasive aspergillosis. J Clin Lab Anal 1998; 12: 257-262.
67. Wiederhold NP, Najvar LK, Vallor AC, et al. Assessment of serum (1→3)-{beta}-D-Glucan as a measure of disease burden in a murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2007; 52: 1176-1178.
68. Mitsutake K, Kohno S, Miyazaki T, et al. Detection of (1-3)-beta- D-glucan in a rat model of aspergillosis. J Clin Lab Anal 1995; 9: 119-122.
69. Brown GD, Gordon S. Fungal beta-glucans and mammalian immunity. Immunity 2003; 19: 311-315.
70. Marty FM, Rubin RH. The prevention of infection posttransplant: The role of prophylaxis, preemptive and empiric therapy. Transpl Int 2006; 19: 2-11.
71. Suda M, Ohno N, Hashimoto T, et al. Kupffer cells play important roles in the metabolic degradation of a soluble antitumor (1→3)-beta-D-glucan, SSG, in mice. FEMS Immunol Med Microbiol 1996; 15: 93-100.
72. Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: A prospective feasibility study. Clin Infect Dis 2005; 41: 1242-50.